Draft on electronic submissions raises concerns for BIO

02/28/2013 | OutSourcing-Pharma.com

Draft guidelines from the FDA on the electronic submission of data from clinical sites don't ensure that industry can rely on technical specifications to allow long-term planning, BIO said. The guidelines should address duplicative submissions that can delay site inspections, Pharmaceutical Research and Manufacturers of America said.

View Full Article in:

OutSourcing-Pharma.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI